Stock SWTX SPRINGWORKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
36.4 USD +0.94% Intraday chart for SpringWorks Therapeutics, Inc. +0.52% -0.27%
06-11 Transcript : SpringWorks Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
06-07 SpringWorks Therapeutics, Inc. Receive Notice of Termination of the Amended and Restated Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
SpringWorks Therapeutics : Termination of Material Agreement Form 8 K
PU
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GL
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
GL
SpringWorks Therapeutics: Q1 Earnings Snapshot
AQ
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
GL
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
GL
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
AQ
SpringWorks Therapeutics: Q4 Earnings Snapshot
AQ
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
GL
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
GL
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
AQ
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
GL
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GL
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. News SpringWorks Therapeutics, Inc.
  5. Press Releases